Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01415167
Recruitment Status : Completed
First Posted : August 11, 2011
Last Update Posted : June 13, 2019
Information provided by (Responsible Party):
Prometheus Laboratories

Brief Summary:
The purpose of this registry is to collect information on patients who are receiving treatment with Proleukin in an organized way, and to learn more about patient care during and after treatment.

Condition or disease
Metastatic Renal Cell Carcinoma Metastatic Melanoma

Detailed Description:

The PROCLAIM Registry is a US-based, multicenter Registry designed to establish a high quality observational database of real-world clinical data on HD IL-2 when used to treat patients with mRCC, mM or other malignancies. The Registry will not, in any way, suggest changes in the treatment or management of the patients enrolled in the Registry. Therefore, physicians will continue to manage and treat patients according to standard of care and their own judgment.

The PROCLAIM Registry will start with a retrospective pilot data collection from a de-identified finite number of patient cases abstracted from their existing medical charts. The features collected will be identical to those planned for the prospective registry. The resulting database will be used to formulate hypotheses to be tested using the prospective registry database. Patients utilized in the retrospective analysis will be excluded from the prospective portion of the Registry.

In the prospective portion of the Registry, sites will enroll patients who are expected to start a course of HD IL-2 therapy. Once enrolled, the patient must receive at least one dose of HD IL-2 to remain in the Registry. Patients will be treated and followed according to the site's standard of care. This Registry will in no way induce changes in the management of individual patients. Clinical data features will be entered into an Electronic Data Capture (EDC) system, and organized into a registry database.

The data contained in the registry database will be observational data. The PROCLAIM Registry does not stipulate patient care, specific visits or interventions but merely surveys standardized parameters regarding HD IL-2 and associated therapies as they are applied by treatment centers. The collection of standard data over time permits the evaluation of trends in patient survival and subsequent therapy exposure. The database will be used to answer future queries formulated by researchers.

Layout table for study information
Study Type : Observational
Actual Enrollment : 1690 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Actual Study Start Date : August 2011
Actual Primary Completion Date : April 2018
Actual Study Completion Date : May 2018

Primary Outcome Measures :
  1. A source of observational data that can be used to report and query patient care patterns, clinical outcomes and trends from high dose IL-2 or Proleukin therapy in treating malignant melanoma, or renal cell carcinoma or other malignancies. [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients starting high dose IL-2 or Proleukin therapy are eligible to participate

Inclusion Criteria:

  • 18 years or older
  • Must have received at least one course of high dose IL-2 or Proleukin
  • Signed informed consent form

Exclusion Criteria:

  • Prior high dose IL-2 or Proleukin therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01415167

Show Show 45 study locations
Sponsors and Collaborators
Prometheus Laboratories
Layout table for investigator information
Study Chair: Michael Wong, MD MD Anderson
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Prometheus Laboratories Identifier: NCT01415167    
Other Study ID Numbers: 10PLK13
First Posted: August 11, 2011    Key Record Dates
Last Update Posted: June 13, 2019
Last Verified: June 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases